- Home
- GUTS vs AVTX Comparison
GUTS vs AVTX Comparison
Compare GUTS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- AVTX
- Stock Information
- Founded
- GUTS 2010
- AVTX 2011
- Country
- GUTS United States
- AVTX United States
- Employees
- GUTS N/A
- AVTX N/A
- Industry
- GUTS
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- AVTX Health Care
- Exchange
- GUTS NYSE
- AVTX Nasdaq
- Market Cap
- GUTS 58.8M
- AVTX 57.4M
- IPO Year
- GUTS 2024
- AVTX 2015
- Fundamental
- Price
- GUTS $1.75
- AVTX $3.67
- Analyst Decision
- GUTS Buy
- AVTX Strong Buy
- Analyst Count
- GUTS 1
- AVTX 6
- Target Price
- GUTS $10.00
- AVTX $34.20
- AVG Volume (30 Days)
- GUTS 264.4K
- AVTX 65.1K
- Earning Date
- GUTS 05-13-2025
- AVTX 05-12-2025
- Dividend Yield
- GUTS N/A
- AVTX N/A
- EPS Growth
- GUTS N/A
- AVTX N/A
- EPS
- GUTS N/A
- AVTX N/A
- Revenue
- GUTS $93,000.00
- AVTX $441,000.00
- Revenue This Year
- GUTS N/A
- AVTX N/A
- Revenue Next Year
- GUTS N/A
- AVTX N/A
- P/E Ratio
- GUTS N/A
- AVTX N/A
- Revenue Growth
- GUTS N/A
- AVTX N/A
- 52 Week Low
- GUTS $0.87
- AVTX $4.15
- 52 Week High
- GUTS $7.89
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- GUTS 62.61
- AVTX 24.71
- Support Level
- GUTS $1.47
- AVTX $4.80
- Resistance Level
- GUTS $1.79
- AVTX $5.26
- Average True Range (ATR)
- GUTS 0.15
- AVTX 0.42
- MACD
- GUTS 0.04
- AVTX -0.04
- Stochastic Oscillator
- GUTS 78.69
- AVTX 0.00
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).